WOLFEL; Thomas

Patent Applications and Registrations

Patent applications and USPTO patent grants for WOLFEL; Thomas.The latest application filed is for "melanoma-associated mhc class i associated oligopeptides and the uses thereof".

Company Profile

0.8.4

WOLFEL; Thomas - Mainz DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof App 20150366957 - EBERTS; Daniela ; et al.	2015-12-24
Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients Grant 8,349,558 - Fatho , et al. January 8, 2	2013-01-08
Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients App 20100035267 - Fatho; Martina ; et al.	2010-02-11
Melanoma-associated MHC class I associated oligopeptides and the uses thereof App 20090104186 - Eberts; Daniela ; et al.	2009-04-23
Method For Identifying Individuals Suffering From A Cellular Abnormality Some Of Whose Abnormal Cells Present Complexes Of Human Leukocyte Antigen Tyrosinase Derived Peptides, And Methods For Treating Said Individuals Grant 6,669,946 - Boon-Falleur , et al. December 30, 2	2003-12-30
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals App 20020128200 - Boon-Falleur, Thierry ; et al.	2002-09-12
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors Grant 6,201,111 - Brichard , et al. March 13, 2	2001-03-13
Precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 6,001,975 - Brichard , et al. December 14, 1	1999-12-14
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,856,091 - Brichard , et al. January 5, 1	1999-01-05
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,854,203 - Brichard , et al. December 29, 1	1998-12-29
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor Grant 5,837,476 - Brichard , et al. November 17, 1	1998-11-17
Isolated, tyrosinase derived peptides and uses thereof Grant 5,530,096 - Wolfel , et al. June 25, 1	1996-06-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.